Stock Analysis
Health Catalyst, Inc. (HCAT) Stock Analysis
Health Catalyst, Inc. (HCAT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Health Catalyst, Inc. (HCAT) currently has an AIQ Score of 50/100, indicating a neutral setup. Value is the strongest factor at 73/100. Quality is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
HCAT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $1.70 |
| AIQ Score | 50/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $126.36M |
| P/E Ratio | 8.55 |
| Forward P/E | — |
| EPS | -$0.55 |
| Revenue TTM | $70.49M |
| Dividend Yield | 0.00% |
| Beta | 1.56 |
| Volume | 264.26K |
| 52-week range | $0.96-$3.62 |
| RSI 14 | 75.76 |
| 50-Day SMA | $1.94 |
| 200-Day SMA | $1.85 |
| Analyst Price Target | $2.08 |
| Next Earnings | Nov 9, 2026 |
HCAT
OverviewHCAT Stock Analysis Summary
Health Catalyst, Inc. (HCAT) currently has an AIQ Score of 50/100, indicating a neutral setup. Value is the strongest factor at 73/100. Quality is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, HCAT has AIQ Score of 50/100 with Value base of 73/100 and fading Quality at 26/100. Wait for component alignment before adding exposure.
Value (73/100) leads while Quality (26/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.73% stock move · HCAT classified in Medical - Healthcare Information Services.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is HCAT Bullish or Bearish Right Now?
HCAT currently has a neutral overall setup. Value is the strongest factor at 73/100, while Quality is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +22.35% upside from the latest quote.
- - Risk Resilience is weak at 39/100.
- - Price is -8.10% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (27 vs 14).
Current Consensus
HCAT's Technical Analysis Consensus is currently Sell, with 14 buy, 4 neutral, and 27 sell votes. HCAT's 14-day RSI is 75.76, which places the stock in an overbought momentum range. HCAT's beta is 1.56, indicating greater market sensitivity than the broad market.
What Changed in HCAT?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the HCAT Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
HCAT Decision Framework
Public evidence layers, setup checks, and risk context for Health Catalyst, Inc..
Health Catalyst, Inc. (HCAT) Stock Analysis
Health Catalyst, Inc. has an AIQ Score of 50/100 in a Neutral regime. Value is strongest at 73/100. Beta is 1.56, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | HCAT is in a Neutral AIQ regime with score 50/100. |
| Signal Conflict | The primary conflict is that value leads at 73/100 while quality lags at 26/100. |
| Factor Evidence | Momentum 58/100 · Value 73/100 · Quality 26/100 · Risk 39/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 73/100.
Momentum is 58/100 and RSI (14) is 75.8.
HCAT is in a Neutral regime at 50/100.
Risk factor is 39/100 with beta 1.56 and annual volatility 89.92%.
Current conflict: value leads at 73/100 while quality lags at 26/100.
HCAT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
HCAT Fundamentals
HCAT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
HCAT Technical Analysis
HCAT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
HCAT Stock Catalysts
Track HCAT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
HCAT Dividend Analysis
HCAT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
HCAT Financial Data
HCAT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
HCAT Risk Analysis
HCAT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
HCAT Stock News
HCAT stock news, market tone, recent headlines, and catalyst context.
HCAT vs Healthcare Services / Managed Care Peers
Current peer cohort: HCAT · HIMS · HSIC · HUM · IQV. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| HCAT Current stock | 50/100 | 73/100 | 58/100 | 39/100 | -0.34 | 89.92% | Current |
| HIMS Hims & Hers Health | 35/100 | 58/100 | 24/100 | 19/100 | -0.19 | 93.21% | HCAT vs HIMS |
| HSIC Henry Schein | 56/100 | 65/100 | 60/100 | 66/100 | 1.03 | 25.76% | HCAT vs HSIC |
| HUM Humana | 56/100 | 55/100 | 83/100 | 62/100 | 1.02 | 47.24% | HCAT vs HUM |
| IQV IQVIA Holdings | 48/100 | 54/100 | 58/100 | 49/100 | 0.97 | 41.33% | HCAT vs IQV |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching HCAT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for HCAT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
HCAT Stock FAQ
What is HCAT stock price today?
Health Catalyst, Inc.'s current stock price is $1.70. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is HCAT bullish or bearish right now?
HCAT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is HCAT's market cap?
HCAT's market cap is $126.36M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is HCAT's current P/E ratio?
HCAT's current P/E ratio is 8.55 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is HCAT's RSI?
HCAT's 14-day RSI is 75.76 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is HCAT above its 50-day and 200-day moving averages?
HCAT is -12.47% from its 50-day SMA and -8.10% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is HCAT's next earnings date?
HCAT's next earnings date is currently listed as Nov 9, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does HCAT pay a dividend?
HCAT's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.